<?xml version="1.0" encoding="UTF-8"?>
<p>The acetylation level of histone and non-histone proteins is an opposing activity regulated by HDACs and histone acetyltransferases (HATs)
 <xref rid="CIT0005" ref-type="bibr">
  <sup>5–7</sup>
 </xref>. The epigenetic acetylation plays a key role in the regulation of fundamental cellular functions including protein phosphorylation, signal transduction, cell cycle, proliferation, apoptosis, cardiac development, and so on
 <xref rid="CIT0008" ref-type="bibr">
  <sup>8–10</sup>
 </xref>. The abnormal expression of HDACs is associated with the pathogenesis of a variety of diseases such as diabetes mellitus
 <xref rid="CIT0011" ref-type="bibr">
  <sup>11</sup>
 </xref>, neurodegenerative diseases
 <xref rid="CIT0012" ref-type="bibr">
  <sup>12</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0013" ref-type="bibr">
  <sup>13</sup>
 </xref>, inflammatory disorders
 <xref rid="CIT0014" ref-type="bibr">
  <sup>14</sup>
 </xref>, HIV
 <xref rid="CIT0015" ref-type="bibr">
  <sup>15–17</sup>
 </xref>, cardiac diseases
 <xref rid="CIT0018" ref-type="bibr">
  <sup>18</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0019" ref-type="bibr">
  <sup>19</sup>
 </xref>, and especially tumor
 <xref rid="CIT0020" ref-type="bibr">
  <sup>20</sup>
 </xref>. Pharmacological inhibition of HDACs and development of HDAC inhibitors (HDACIs) have been widely investigated in the treatment of cancer and other diseases
 <xref rid="CIT0021" ref-type="bibr">
  <sup>21</sup>
 </xref>.
</p>
